HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TXG
10x Genomics, Inc.
TXG lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TXG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Strong | |
| Unavailable |
TXG's cash flow is currently strong, and its revenue is stable, but its profitability is under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TXG PE Valuation
TXG has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TXG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
TXG has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TXG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.52 | +$0.10 |
| Q2 2026 | -$0.59 | +$0.11 |
| Q1 2026 | -$0.17 | +$1.13 |
| Q4 2025 | -$0.35 | +$1.17 |
| Q3 2025 | -$0.62 | +$0.92 |
| Q2 2025 | -$0.70 | +$1.33 |
| Q1 2025 | -$1.30 | +$0.94 |
| Q4 2024 | -$1.52 | +$0.66 |
TXG has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over TXG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over TXG on profitability, with a higher operating margin.
TXG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $150.7M | +1.1% |
| Q2 2026 | $151M | -13% |
| Q1 2026 | $150.8M | -2.6% |
| Q4 2025 | $166M | +0.6% |
| Q3 2025 | $149M | -1.7% |
| Q2 2025 | $172.9M | +13% |
| Q1 2025 | $154.9M | +9.8% |
| Q4 2024 | $165M | -10% |
TXG's revenue fell from its 2023 peak and has held roughly level since: $151M last quarter, up 1.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -11% | +11 points |
| Q2 2026 | -13% | -30 points |
| Q1 2026 | -11% | +14 points |
| Q4 2025 | -12% | +18 points |
| Q3 2025 | -22% | +5.7 points |
| Q2 2025 | 17% | +45 points |
| Q1 2025 | -25% | +18 points |
| Q4 2024 | -30% | -0.2 points |
TXG's operating margin was −11% last quarter, up 11 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over TXG on cash flow, with more consistent year-over-year improvement.
TXG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $14.9M | -65% |
| Q2 2026 | $15.4M | -4.6% |
| Q1 2026 | $24.5M | -24% |
| Q4 2025 | $39M | +$48.5M |
| Q3 2025 | $42.5M | +140% |
| Q2 2025 | $16.1M | +249% |
| Q1 2025 | $32.5M | +$51.1M |
| Q4 2024 | -$9.5M | -142% |
TXG has burned cash in most quarters: $94M over the past year, up 15% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TXG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TXG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +822K shares |
| 1 year | +4.2% | +5.3M shares |
| 3 years | +11% | +13.1M shares |
| 5 years | +18% | +19.9M shares |
| Available history | +35% | +34M shares |
TXG has 131M diluted shares, up 4.2% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TXG Net Leverage
TXG's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TXG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.2 | Neutral |
| Stochastic | 28.5 | Neutral |
TXG's weekly RSI is 52 (neutral) and its Stochastic is 28 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TXG PE vs Healthcare Sector
TXG has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TXG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $73.7 | 20% below |
| 20 week MA | $62.6 | 5.5% below |
| 50 week MA | $38.3 | 54% above |
| 100 week MA | $25.3 | 134% above |
| 200 week MA | $31.8 | 86% above |
TXG has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
TXG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $78.2 | $151.3 | +94% |
| 2021 | $151.3 | $146.1 | -3.5% |
| 2022 | $146.1 | $34.2 | -77% |
| 2023 | $34.2 | $56.0 | +63% |
| 2024 | $56.0 | $14.6 | -74% |
| 2025 | $14.6 | $16.5 | +13% |
| 2026 YTD | $16.5 | $59.1 | +258% |
TXG has the edge over HIMS on returns for 2026, with the stronger performance.